New simplified structure and operational set-up supports Novartis strategy as a focused medicines company and is designed to power next phase of innovation, growth and productivity
Intas has developed a biosimilar of Lucentis, which is currently under Phase III global trial for submission in major countries including EMA & the US
The investment will significantly enhance the development of high-purity lipid systems, essential delivery systems for next generation nucleic acid drugs such as mRNA vaccines
Through this consortium, Lonza will collaborate with other industry leaders to advance the research and development of inhalation technologies
Celerity Pharmaceuticals uses Biocon Biologics’ insulin drug substance to develop the product
Through this partnership, Premas will connect with genomics labs to provide automated NGS solutions
An estimated 21 million American women experience BV
Arzeda harnesses the power of computer-designed enzymes and applies the latest advances in digital biology
The plant is scheduled to come on stream in September 2024
The new structure further transitions the Health Care business line into a system solutions partner for the pharmaceutical and biotech industries
Subscribe To Our Newsletter & Stay Updated
